Sertindole for schizophrenia

Efficacy and Safety of Sertindole in Schizophrenia

“…[24][25][26] Owing to its pharmacological profile, sertindole demonstrated efficacy in treating positive, negative, and cognitive symptoms, 27,[39][40][41][42][43][44]47,48 a low potential to cause sedation and EPS, 9,71 ) and an acceptable metabolic profile. Sertindole has a high affinity for serotonin 5-HT2A and 5-HT2C and α1 adrenergic receptors; its affinity for dopamine D2 receptors is more pronounced in limbic rather than nigrostriatal system.…”

“…Studies comparing sertindole with risperidone showed a significantly lower incidence of EPS among sertindole-treated patients. 17 Similar to other atypical antipsychotics, sertindole induced a significant greater mean weight gain versus placebo and haloperidol 9,41,42,71 ; when compared with risperidone, both treatments were associated with a moderate increase in weight gain and body mass index but with no increased risk of metabolic syndrome. 41 The favorable profile of sertindole on EPS was confirmed by the meta-analysis of Leucht et al, which showed that sertindole (mean ORs, 0.17-0.2) produced fewer EPS than placebo and almost all other drugs and was preceded in ranking only by clozapine (mean ORs, 0.06-0.40).…”

Efficacy and Safety of Sertindole in Schizophrenia

“…[24][25][26] Owing to its pharmacological profile, sertindole demonstrated efficacy in treating positive, negative, and cognitive symptoms, 27,[39][40][41][42][43][44]47,48 a low potential to cause sedation and EPS, 9,71 ) and an acceptable metabolic profile. Sertindole has a high affinity for serotonin 5-HT2A and 5-HT2C and α1 adrenergic receptors; its affinity for dopamine D2 receptors is more pronounced in limbic rather than nigrostriatal system.…”

“…Studies comparing sertindole with risperidone showed a significantly lower incidence of EPS among sertindole-treated patients. 17 Similar to other atypical antipsychotics, sertindole induced a significant greater mean weight gain versus placebo and haloperidol 9,41,42,71 ; when compared with risperidone, both treatments were associated with a moderate increase in weight gain and body mass index but with no increased risk of metabolic syndrome. 41 The favorable profile of sertindole on EPS was confirmed by the meta-analysis of Leucht et al, which showed that sertindole (mean ORs, 0.17-0.2) produced fewer EPS than placebo and almost all other drugs and was preceded in ranking only by clozapine (mean ORs, 0.06-0.40).…”

Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008–2024)

“…Similarly, zotepine, approved in Germany and Japan, offers an alternative to clozapine for treatment-resistant schizophrenia, with significant improvements in both positive and negative symptoms and minimal EPS ( DeSilva et al, 2006 ; Lin et al, 2013 ; Palmgren et al, 2000 ). Lastly, sertindole combines efficacy in addressing negative symptoms with a favorable metabolic and EPS profile, although concerns about QT prolongation led to its withdrawal and subsequent reintroduction under strict monitoring ( Juruena et al, 2011 ; Lewis et al, 2000 ; Cincotta and Rodefer, 2010 ; Pae, 2013 ).…”

Sertindole versus other atypical antipsychotics for schizophrenia

“…A previous systematic review compared sertindole with any other treatment (Lewis 2005). It could not draw a conclusion on the effects of sertindole compared to other second generation antipsychotic drugs, because, at that time, no relevant studies were available.…”

Efficacy and Safety of Sertindole in Schizophrenia

“…[24][25][26] Owing to its pharmacological profile, sertindole demonstrated efficacy in treating positive, negative, and cognitive symptoms, 27,[39][40][41][42][43][44]47,48 a low potential to cause sedation and EPS, 9,71 ) and an acceptable metabolic profile. Sertindole has a high affinity for serotonin 5-HT2A and 5-HT2C and α1 adrenergic receptors; its affinity for dopamine D2 receptors is more pronounced in limbic rather than nigrostriatal system.…”

“…Studies comparing sertindole with risperidone showed a significantly lower incidence of EPS among sertindole-treated patients. 17 Similar to other atypical antipsychotics, sertindole induced a significant greater mean weight gain versus placebo and haloperidol 9,41,42,71 ; when compared with risperidone, both treatments were associated with a moderate increase in weight gain and body mass index but with no increased risk of metabolic syndrome. 41 The favorable profile of sertindole on EPS was confirmed by the meta-analysis of Leucht et al, which showed that sertindole (mean ORs, 0.17-0.2) produced fewer EPS than placebo and almost all other drugs and was preceded in ranking only by clozapine (mean ORs, 0.06-0.40).…”

Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008–2024)

“…Similarly, zotepine, approved in Germany and Japan, offers an alternative to clozapine for treatment-resistant schizophrenia, with significant improvements in both positive and negative symptoms and minimal EPS ( DeSilva et al, 2006 ; Lin et al, 2013 ; Palmgren et al, 2000 ). Lastly, sertindole combines efficacy in addressing negative symptoms with a favorable metabolic and EPS profile, although concerns about QT prolongation led to its withdrawal and subsequent reintroduction under strict monitoring ( Juruena et al, 2011 ; Lewis et al, 2000 ; Cincotta and Rodefer, 2010 ; Pae, 2013 ).…”

Sertindole versus other atypical antipsychotics for schizophrenia

“…A previous systematic review compared sertindole with any other treatment (Lewis 2005). It could not draw a conclusion on the effects of sertindole compared to other second generation antipsychotic drugs, because, at that time, no relevant studies were available.…”

Efficacy and Safety of Sertindole in Schizophrenia

“…[24][25][26] Owing to its pharmacological profile, sertindole demonstrated efficacy in treating positive, negative, and cognitive symptoms, 27,[39][40][41][42][43][44]47,48 a low potential to cause sedation and EPS, 9,71 ) and an acceptable metabolic profile. Sertindole has a high affinity for serotonin 5-HT2A and 5-HT2C and α1 adrenergic receptors; its affinity for dopamine D2 receptors is more pronounced in limbic rather than nigrostriatal system.…”

“…Studies comparing sertindole with risperidone showed a significantly lower incidence of EPS among sertindole-treated patients. 17 Similar to other atypical antipsychotics, sertindole induced a significant greater mean weight gain versus placebo and haloperidol 9,41,42,71 ; when compared with risperidone, both treatments were associated with a moderate increase in weight gain and body mass index but with no increased risk of metabolic syndrome. 41 The favorable profile of sertindole on EPS was confirmed by the meta-analysis of Leucht et al, which showed that sertindole (mean ORs, 0.17-0.2) produced fewer EPS than placebo and almost all other drugs and was preceded in ranking only by clozapine (mean ORs, 0.06-0.40).…”

Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008–2024)

“…Similarly, zotepine, approved in Germany and Japan, offers an alternative to clozapine for treatment-resistant schizophrenia, with significant improvements in both positive and negative symptoms and minimal EPS ( DeSilva et al, 2006 ; Lin et al, 2013 ; Palmgren et al, 2000 ). Lastly, sertindole combines efficacy in addressing negative symptoms with a favorable metabolic and EPS profile, although concerns about QT prolongation led to its withdrawal and subsequent reintroduction under strict monitoring ( Juruena et al, 2011 ; Lewis et al, 2000 ; Cincotta and Rodefer, 2010 ; Pae, 2013 ).…”

Sertindole versus other atypical antipsychotics for schizophrenia

“…A previous systematic review compared sertindole with any other treatment (Lewis 2005). It could not draw a conclusion on the effects of sertindole compared to other second generation antipsychotic drugs, because, at that time, no relevant studies were available.…”